Pyxis Oncology’s (PYXS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $8.00 target price on the stock, down from their prior target price of $10.00.

PYXS has been the topic of a number of other research reports. Stephens started coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.43.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.69 on Friday. Pyxis Oncology has a one year low of $1.49 and a one year high of $6.85. The firm has a market cap of $100.50 million, a P/E ratio of -1.64 and a beta of 1.00. The stock’s 50-day moving average is $2.93 and its 200-day moving average is $3.30.

Insider Activity

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the acquisition, the chief financial officer now owns 1,199,143 shares in the company, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.80% of the stock is owned by corporate insiders.

Institutional Trading of Pyxis Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC grew its position in shares of Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after acquiring an additional 743,499 shares during the period. Geode Capital Management LLC increased its position in Pyxis Oncology by 5.5% during the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after buying an additional 57,016 shares during the last quarter. Blue Owl Capital Holdings LP bought a new stake in Pyxis Oncology in the second quarter valued at approximately $3,462,000. State Street Corp lifted its position in shares of Pyxis Oncology by 28.0% in the third quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after buying an additional 208,344 shares during the last quarter. Finally, abrdn plc boosted its stake in shares of Pyxis Oncology by 28.9% during the 3rd quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after acquiring an additional 204,742 shares during the period. 39.09% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.